Clovis Oncology (CLVS) stock forecast for 2023
Last update: 06-24-2022, 6:24Sector: Healthcare
The share price of Clovis Oncology, Inc. (CLVS) now
What analysts predict:: $3
52-week high/low: $6.65 / $0.581
50/200 Day Moving Average: $1.317 / $2.62
This figure corresponds to the average price over the previous 50/200 days. For Clovis Oncology stocks, the 50-day moving average is the resistance level today.
For Clovis Oncology stocks, the 200-day moving average is the resistance level today.
Are you interested in Clovis Oncology stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Clovis Oncology stock price in 2023. How much will one Clovis Oncology share be worth in 2023?
Is it worth taking profit / loss on Clovis Oncology stock now or waiting? What are analysts' forecasts for Clovis Oncology stock?
We forecast Clovis Oncology stock performance using neural networks based on historical data on Clovis Oncology stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Clovis Oncology stock prediction results are shown below and presented as a graph, table and text information.
Clovis Oncology stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Clovis Oncology analysts is $3.
Today 200 Day Moving Average is the resistance level (2.62 $).
50 Day Moving Average is the resistance level (1.317 $).
Historical and forecast chart of Clovis Oncology stock
The chart below shows the historical price of Clovis Oncology stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Clovis Oncology stock price can be found in the table below.
Clovis Oncology (CLVS) Forecast for 2023
Clovis Oncology information and performance
Clovis Oncology, Inc., a biopharmaceutical company, specializes in the acquisition, development and commercialization of anti-cancer agents in the United States, the European Union and internationally. The company offers Rubraca (rucaparib), an oral small molecule poly-ADP-ribose polymerase inhibitor for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Clovis Oncology Address
5500 FLATIRON PARKWAY, SUITE 100, BOULDER, CO, US
Market Capitalization: 220 135 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -358 064 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: 0.13
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: -0.1
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 5.29
Enterprise Value (EV) /Revenue
EV To EBITDA: -
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 143879000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Clovis Oncology price target for 2021 by month
Target values for the price of one Clovis Oncology share for Jan 2023.
Pessimistic target level: 1.37
Optimistic target level: 2.12
Target values for the price of one Clovis Oncology share for Feb 2023.
Pessimistic target level: 1.69
Optimistic target level: 2.03
Target values for the price of one Clovis Oncology share for Mar 2023.
Pessimistic target level: 1.67
Optimistic target level: 2.08
Target values for the price of one Clovis Oncology share for Apr 2023.
Pessimistic target level: 1.76
Optimistic target level: 2.53
Target values for the price of one Clovis Oncology share for May 2023.
Pessimistic target level: 1.53
Optimistic target level: 1.87
Target values for the price of one Clovis Oncology share for Jun 2023.
Pessimistic target level: 1.19
Optimistic target level: 1.58
Target values for the price of one Clovis Oncology share for Jul 2023.
Pessimistic target level: 1.26
Optimistic target level: 1.93
Target values for the price of one Clovis Oncology share for Aug 2023.
Pessimistic target level: 1.59
Optimistic target level: 2.09
Target values for the price of one Clovis Oncology share for Sep 2023.
Pessimistic target level: 1.39
Optimistic target level: 1.97
Target values for the price of one Clovis Oncology share for Oct 2023.
Pessimistic target level: 1.82
Optimistic target level: 2.45
Target values for the price of one Clovis Oncology share for Nov 2023.
Pessimistic target level: 1.68
Optimistic target level: 2.25
Target values for the price of one Clovis Oncology share for Dec 2023.
Pessimistic target level: 1.53
Optimistic target level: 2.03
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.